When the Farmer Pills Run Out, the Hunter's Toolkit Can be Real and Powerful

Four years into the stimulant shortage, here’s what every Hunter should be relearning.

Image by Dee from Pixabay

Four years in, with no end in sight, the U.S. stimulant shortage has become one of the strangest, longest-running, and most quietly destabilizing public health stories of our time.

It started in October 2022 with a labor problem at a single Teva plant. It’s now stretched well into 2026, pulling in nearly every major manufacturer, every dosage strength, both the amphetamine and methylphenidate families, and an estimated 15.5 million American adults with ADHD diagnoses, more than seventy percent of whom reported difficulty filling their prescriptions during the worst stretches.

I’ve been hearing from readers for years now. The same story over and over. Five pharmacies, nobody has it. Switched from Adderall to Vyvanse, switched from Vyvanse to Concerta, switched from Concerta to compounding, switched again.

Phone trees. Insurance denials. Going without for weeks. Anxiety about the next refill bleeding into anxiety about everything else. The system is failing them, and it’s been failing them for so long now that “failing” doesn’t quite capture it. It’s the new normal.

A new analysis published in JAMA Health Forum and reported by CIDRAP last month traces the structural roots of the shortage further than most reporting has gone. It isn’t really about over-prescribing. And it isn’t really about telehealth expansion, despite what the DEA likes to imply.

It’s really about how fragile our pharmaceutical supply chain has become, and how rigidly the federal government regulates a category of medications it has classified as suspect from the start.

Let me unpack that, because it matters.

The active pharmaceutical ingredients for most ADHD stimulants come from overseas. When the global supply chain hiccupped in late 2022, U.S. imports of raw amphetamine and a key precursor called phenylacetone contracted sharply, and several mid-sized manufacturers cut production almost simultaneously. The shortage that followed wasn’t really an American shortage; it was the American end of a global problem.

But the global supply problem is only half of it. The other half, the half that actually controls how much medication can reach patients, is the DEA’s annual quota system.

Stimulants are Schedule II controlled substances, which means the DEA sets a hard cap each year on how much active ingredient any manufacturer can possess. The cap is based on backward-looking sales data. Which is to say, on what the country bought last year.

Not on what people need this year. Not on the rising adult diagnoses of the last decade. Not on the explosion of late-diagnosed women in their thirties and forties. Last year’s sales, capped, multiplied out, and good luck.

And that tells you something about the people running the system.

We have a Farmer-style bureaucracy that looks at last year’s harvest, projects forward a similar harvest, and writes the regulations accordingly. It assumes the world is stable, that the past predicts the future, that variability is something to be smoothed out rather than planned for.

A Hunter-style approach would do the opposite. It would build redundancy into the system, source ingredients from multiple regions, hold reserves for surge demand, react quickly when the early signal of a problem appeared, and assume that any complex system will at some point break in ways nobody predicted.

Hunters plan for change. Farmers plan for repetition. Our entire stimulant supply chain, from the API sourcing to the DEA caps, is a Farmer system. And that’s why it’s been failing Hunters for four years and counting.

Here’s where it gets useful, though.

A landmark study published in Cell last December found that stimulant medications don’t actually act on the brain’s attention networks at all. They act on its wakefulness and reward systems. Stimulants raise arousal and pre-load the reward circuitry, which lets a Hunter brain feel awake and engaged enough to stay on a Farmer task. That’s my under-arousal/thalamic-gain theory, validated by modern brain imaging.

Read inside that frame, the shortage looks different. (Not less painful, but different.) If stimulants are operating on arousal and reward, and if a Hunter is suddenly without them, then the question becomes, what else raises arousal and reward in a Hunter brain?

And the answer turns out to be most of the things human beings did with their bodies for the half million years before we invented prescription pharmaceuticals.

Movement raises arousal. A vigorous half hour of physical activity, especially first thing in the morning, can shift a Hunter brain from foggy to engaged for hours afterward.

Sleep raises arousal in a different and equally important way. The same Cell paper noted that adequate sleep replicates many of the effects stimulants produce, and that about half of children and adults aren’t getting enough.

Novelty raises arousal. So does meaningful work. So does sunlight in the eyes within thirty minutes of waking. So does cold water on the face or the body. So does eating real food at regular intervals. So does being in nature for any length of time. So does being deeply engaged with something you actually care about, instead of grinding through something you don’t.

I’m not going to tell you any of this is a substitute for medication if you genuinely need medication: for some Hunters, the stimulant is the difference between functioning and not, and the shortage is causing real suffering for them. I take that seriously, and I’m not minimizing it.

But I am saying the shortage has forced a national rediscovery of something Hunters used to know. The pill is one tool, but it isn’t the only tool. And the Hunters I’ve watched ride this shortage out the best are the ones who’d already built the rest of the toolbox before the supply chain failed them.

A personal note. I’ve had ADHD all my life, and decades of experience on both sides of the medication question. What I can tell you is that the foundation underneath any pharmacological intervention matters more than most pediatricians will ever explain to you.

Sleep, movement, sunlight, novelty, real engagement with real work, time with people who actually understand you. Build that, and you have something. Don’t build it, and the medication carries weight it was never meant to carry by itself. And you discover that fact in the worst possible way the first time the pharmacy runs dry.

The shortage isn’t going away soon. Even with a 25% DEA quota increase in late 2025, supply still hasn’t caught up to demand, and the structural causes (foreign API sourcing, restrictive quotas, manufacturer concentration) haven’t been fixed. The smartest move any Hunter can make right now is to assume the disruption will continue, and to use the next year to build the underneath part of the toolbox while you still have time.

If your medication is currently working, build the foundation now. If your medication has gone missing, start with sleep and movement and sunlight and food, and rebuild from there.

If you’ve never had access to medication in the first place, know that the older Hunter toolkit is real, it’s powerful, and it’s been doing the job for longer than pharmacology has existed.

If this resonates, share it with the Hunter you know who’s been white-knuckling the shortage. And subscribe if you haven’t yet. We’ve got a lot more ground to cover.